二甲双胍与格列美脲对早期糖尿病肾病患者纤溶酶原活性的作用  

Effects of metformin and glimepiride on plasminogen activity in early patients with diabetic nephropathy

作　　者：郭冠芬[1] 张秀薇[1] 刘玉华[1] 刘衬连[1] 

机构地区：[1]广东省东莞市人民医院内分泌科,广东东莞523000

出　　处：《中国现代医生》2014年第11期138-139,142,共3页China Modern Doctor

摘　　要：目的探讨二甲双胍、格列美脲对早期糖尿病肾病患者组织纤溶酶原激活剂(t-PA)及纤溶酶原激活物抑制剂-1(PAI-1)水平的影响。方法 60例早期糖尿病肾病患者分为两组,分别接受格列美脲、二甲双胍治疗,比较两组治疗3个月前后患者血糖控制情况及血t-PA、PAI-1水平的变化。结果与治疗前相比,治疗后两组患者的FPG、HOMA指数均明显下降,血T-PA水平明显升高,同时血PAI-1水平显著下降,差异有统计学意义(P<0.05)。结论二甲双胍、格列美脲对早期糖尿病肾病患者除改善血糖控制外,还能改善患者的纤溶系统功能。Objective To study the effects of metformin and glimepiride on tissue-type plasminogen activator （t-PA） and plasminogen activator inhibitor 1 （PAI-1） in early diabetic nephropathy（DN） patients. Methods Sixty DN patients were divided into two groups and received glimepiride or metformin trearment respectively for 3 months. The glycemic control and the level of serum t-PA and PAI-1 before and 3 months after treatment were observed. Results After 3 months with metformin or glimepiride treatment, the FPG level and HOMA index were significantly lower, and there was significant promotion in the level of serum t-PA and reductions in the level of serum PAI-1. Conclusion Both glimepiride and metformin can improve glycemic control and plasminogen activity in early DN patients.

关 键 词：格列美脲 二甲双胍 糖尿病肾病 纤溶酶原激活剂抑制物-1 组织纤溶酶原激活剂 

分 类 号：R587.1[医药卫生—内分泌]